Drugs / PKI-179
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00997360 | Feb 2010 → Feb 2012 | cancer | Wyeth is now a wholly owned subsidiary of Pfizer | Withdrawn | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PKI-179 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00997360 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL1258517 ↗1“PI3-kinase p110-alpha subunit inhibitor” CHEMBL1258517 ↗ |
| Modality | Small molecule | — CHEMBL1258517 ↗ |
| Route | Oral | “All subjects will receive daily oral dosing of PKI-179.” NCT00997360 ↗ |
| Target | MTOR | “Serine/threonine-protein kinase mTOR inhibitor” CHEMBL1258517 ↗ |
| Target | PIK3CA | “PI3-kinase p110-alpha subunit inhibitor” CHEMBL1258517 ↗ |